4HG0 Stock Chart & Stats
€0.25
-€0.01(-8.07%)
At close: 4:00 PM EST
€0.25
-€0.01(-8.07%)
Day’s Range― - ―
52-Week Range€0.09 - €0.40
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€4.78M
Enterprise Value€18.93
Total Cash (Recent Filing)€6.63M
Total Debt (Recent Filing)€8.71M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.27
Shares Outstanding28,874,178
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-4.74
Price to Sales (P/S)109.73
P/FCF Ratio-1.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-11.77
Revenue Forecast (FY)€10.82M
Bulls Say, Bears Say
Bulls Say
Near-Patient Diagnostics PlatformThe platform targets convenient testing outside traditional laboratories, while digital follow-up can support recurring use and broader access. If commercial execution improves, this model could provide scalable exposure to decentralized diagnostics and health monitoring.
TTM Equity Turned PositiveA return to positive equity provides a stronger capital base than the prior periods of negative equity and may modestly improve financial resilience. However, the benefit remains limited because debt is still high and accumulated losses indicate substantial balance-sheet pressure.
Reported Revenue Growth MetricThe reported revenue-growth metric indicates some underlying period-to-period expansion in the available fundamentals data. Sustained growth would be important for absorbing the cost base, although the latest financial summary separately reports declining TTM revenue and therefore does not confirm a durable trend.
Bears Say
High LeverageDebt materially exceeds the current equity base, leaving limited balance-sheet flexibility. This increases refinancing and funding pressure while the company remains loss-making, potentially restricting investment in product development and commercial expansion over the medium term.
Persistent Cash BurnContinued operating and free-cash-flow deficits show that the business is not yet self-funding. Without a material improvement in revenue or costs, ongoing cash consumption could require external financing, creating dilution or additional leverage and limiting strategic flexibility.
Weak Commercial Traction And ProfitabilityVery low and declining revenue is insufficient to support the existing cost base, while negative gross profit and deeply negative operating and net margins show limited current operating leverage. Persistent losses weaken the capacity to fund commercialization internally.
4HG0 FAQ
What was Qlife Holding AB’s price range in the past 12 months?
Qlife Holding AB lowest stock price was €0.09 and its highest was €0.40 in the past 12 months.
What is Qlife Holding AB’s market cap?
Qlife Holding AB’s market cap is €4.78M.
When is Qlife Holding AB’s upcoming earnings report date?
Qlife Holding AB’s upcoming earnings report date is Aug 26, 2026 which is in 5 days.
How were Qlife Holding AB’s earnings last quarter?
Qlife Holding AB released its earnings results on May 13, 2026. The company reported -€0.065 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Qlife Holding AB overvalued?
According to Wall Street analysts Qlife Holding AB’s price is currently Overvalued.
Does Qlife Holding AB pay dividends?
Qlife Holding AB does not currently pay dividends.
What is Qlife Holding AB’s EPS estimate?
Qlife Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Qlife Holding AB have?
Qlife Holding AB has 28,874,178 shares outstanding.
What happened to Qlife Holding AB’s price movement after its last earnings report?
Qlife Holding AB reported an EPS of -€0.065 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.041%.
Which hedge fund is a major shareholder of Qlife Holding AB?
Currently, no hedge funds are holding shares in DE:4HG0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Qlife Holding AB
Operating as a medical technology firm, Qlife Holding AB (publ) specializes in the production and distribution of in-vitro diagnostic instruments and their associated chemical reagents. Their flagship offering is the Egoo.Health Platform, a comprehensive system comprising a measuring device, single-use test capsules, and integrated software. This innovative platform facilitates the detection of various biomarkers or viral agents, with each capsule tailored for a distinct diagnostic purpose. The range of supported biomarkers encompasses C-reactive protein for home-based monitoring, Phenylalanine (PHE) vital for managing Phenylketonuria (PKU) in patients, and a multiplex test designed to identify Sars-CoV-2 and Influenza, aiding in the detection of viral and bacterial infections. Established in 2019, Qlife's operations are headquartered in Helsingborg, Sweden.